Endoglin Requirement for BMP9 Signaling in Endothelial Cells Reveals New Mechanism of Action for Selective Anti-Endoglin Antibodies

• Olivier Nolan-Stevaux ,

  Contributed equally to this work with: Olivier Nolan-Stevaux, Wendy Zhong

  * E-mail: oliviern@amgen.com

  Affiliation Oncology Research, Amgen, South San Francisco, California, United States of America

  ⨯
• Wendy Zhong ,

  Contributed equally to this work with: Olivier Nolan-Stevaux, Wendy Zhong

  Affiliation Oncology Research, Amgen, South San Francisco, California, United States of America

  ⨯
• Stacey Culp,

  Affiliation Therapeutic Discovery, Amgen, Seattle, Washington, United States of America

  ⨯
• Kathy Shaffer,

  Affiliation Therapeutic Discovery, Amgen, Seattle, Washington, United States of America

  ⨯
• Joseph Hoover,

  Affiliation Therapeutic Discovery, Amgen, Seattle, Washington, United States of America

  ⨯
• Dineli Wickramasinghe,

  Affiliation Oncology Research, Amgen, South San Francisco, California, United States of America

  ⨯
• Astrid Ruefli-Brasse

  Affiliation Oncology Research, Amgen, South San Francisco, California, United States of America

  ⨯